Healthcare Resource Utilisation of Severe Uncontrolled T2low and Non-T2low Asthma in Finland During 2018-2021
Josefine Persson,Juhani Aakko,Saara Kaijala,Mariann Lassenius,Arja Viinanen,Hannu Kankaanranta,Lauri Lehtimäki
DOI: https://doi.org/10.2147/jaa.s455911
2024-07-19
Journal of Asthma and Allergy
Abstract:Josefine Persson, 1 Juhani Aakko, 2 Saara Kaijala, 2 Mariann I Lassenius, 2 Arja Viinanen, 3 Hannu Kankaanranta, 4 Lauri Lehtimäki 5 1 AstraZeneca, Nordic, Mölndal, Sweden; 2 Medaffcon Oy, Espoo, Finland; 3 Turku University Hospital, Division of Medicine, Department of Pulmonary Diseases and the University of Turku, Department of Pulmonary Diseases and Clinical Allergology, Turku, Finland; 4 Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; 5 Allergy Centre, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland Correspondence: Josefine Persson, AstraZeneca AB, Pepparedsleden 1, Mölndal, 431 83, Sweden, Email Purpose: Patients with asthma and low levels of type 2 inflammatory biomarkers (T2 low) have limited effective treatment options. Such biomarkers include eg blood eosinophils (b-eos) and fractional exhaled nitric oxide (FeNO). The healthcare resource utilisation (HCRU) of severe uncontrolled T2 low asthma remains unexplored. Thus, this study aimed to estimate the HCRU of T2 low and non-T2 low severe uncontrolled asthma patients using real-world data in Finland. Patients and Methods: Adult patients with an asthma diagnosis during baseline (2012– 2017) at the pulmonary department of Turku University Hospital were included and followed during 2018– 2021, or until death. Total HCRU costs and respiratory-related HCRU costs were evaluated. The main drivers for the HCRU and costs were assessed with gamma and negative binomial regression models. Results: Of the severe uncontrolled asthma patients with T2 status available, 40% (N=66) were identified with T2 low and 60% (N=103) with non-T2 low asthma. The average cumulative cost per patient was similar in patients with T2 low compared with non-T2 low, with all-cause costs cumulating in four years of follow-up to 37,524€ (95% CI: 27,160, 47,888) in T2 low compared to 34,712€ (25,484, 43,940) in non-T2 low. The corresponding average cumulative respiratory-related costs were 5178€ (3150, 7205) in T2 low compared to 5209€ (4104, 6313) in non-T2 low. Regression modelling identified no differences between the T2-status groups when assessing all-cause healthcare costs per patient-year (PPY). On the other hand, the regression modelling predicted more inpatient days PPY for severe uncontrolled patients with T2 low status compared to the patients with non-T2 low status. Conclusion: Patients with uncontrolled severe T2 low asthma use equal healthcare resources as corresponding non-T2 low patients. This study brought new insights into the HCRU of severe uncontrolled asthma patients per T2 status, which has not previously been investigated. Keywords: severe uncontrolled asthma, phenotypes, healthcare resource utilisation, economic burden, real-world evidence The global prevalence of asthma has been estimated to be 4.4%, with a range between 2.2% in low-income countries and 10.2% in high-income countries. 1 In Finland, the prevalence has been estimated to be around 10% and has increased in recent decades. 2 Asthma has a high economic burden on healthcare, mainly driven by poor control of asthma symptoms and exacerbation events. 3 A review from 2017, 4 indicated that the healthcare resource utilisation (HRCU) of mild, moderate, and, severe asthma varied between countries, with a mean asthma-related cost per patient per year in Europe of 1790€, and in the US of 2900€. Severe asthma is defined as asthma that is uncontrolled, despite adherence with maximally optimised high-dose inhaled corticosteroids with a second controller and management of contributory factors, or that requires high-dose treatment to maintain good symptom control and reduce the risk of exacerbations. 5 In the Nordic countries, the prevalence of severe asthma among asthmatic patients has been estimated to be 3.5–9.5%. 6–8 Patients with severe asthma have a higher risk of exacerbation events, 9 which is the main driver for asthma-related HCRU costs. 10 Several studies have estimated the economic burden of severe asthma in Europe. A Spanish study from 2018, 11 estimated the mean annual direct cost per patient to be 7472€, and in a French cohort study from 2018, 12 the mean annual asthma-related cost per patient was estimated to be 8222€. Another study from France, analysing t -Abstract Truncated-
immunology,allergy,respiratory system